Antengene Corporation Limited (HKG:6996)

Hong Kong · Delayed Price · Currency is HKD

4.830

+0.130 (2.77%)

At close: Mar 27, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research Development and Commercialisation of Pharmaceutical Products	105.34M	91.95M	67.31M	160.14M	28.77M
Research Development and Commercialisation of Pharmaceutical Products Growth	14.56%	36.62%	-57.97%	456.62%	-
Total	105.34M	91.95M	67.31M	160.14M	28.77M
Total Growth	14.56%	36.62%	-57.97%	456.62%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	85.73M	72.26M	56.70M	-	-
Mainland China Growth	18.64%	27.44%	-	-	-
Other Countries/Regions	19.61M	19.69M	10.61M	5.27M	238.00K
Other Countries/Regions Growth	-0.41%	85.69%	101.42%	2112.18%	-
Greater China	-	-	-	154.87M	28.53M
Greater China Growth	-	-	-	442.81%	-
Total	105.34M	91.95M	67.31M	160.14M	28.77M
Total Growth	14.56%	36.62%	-57.97%	456.62%	-

Source: S&P Global Market Intelligence.